<DOC>
	<DOCNO>NCT00347048</DOCNO>
	<brief_summary>This study consist 2-week placebo-controlled double-blind inter-group efficacy study moderate severe refractory ulcerative colitis ( UC ) patient follow maximum 12-week open-label efficacy safety study responder .</brief_summary>
	<brief_title>Tacrolimus ( FK506 ) Study Moderate Severe Refractory Ulcerative Colitis Patients</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Moderate severe refractory UC patient Disease activity : 4 time stool day , bloody stool , moderate severe endoscopic find Steroid resistance dependence meet least one follow condition : efficacy 40mg/day 1mg/kg/day steroid least 1 week , efficacy 3040mg/day steroid least 2 week , exacerbation along steroid reduction Mild fulminant type Renal failure patient , hepatic failure patient Patients take 6mercaptopurine , cyclosporin immunosuppressant within 12 week prior entry Patients receive LCAP GCAP within 2 week prior entry Patients change dose steroid start steroid within 2 week prior entry . Patients change dose steroid start steroid within 1 week prior entry case receive 40 mg/ day 1mg/kg/day steroid study .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Ulcerative colitis</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>FK506</keyword>
	<keyword>treatment outcome</keyword>
</DOC>